FAST Company

Catena Biosciences

Current approaches for autoimmune therapies rely on symptom mitigation and inflammation reduction and require chronic medication for the patient’s lifetime. What is sorely needed is a disease modifying approach that targets the upstream cause of autoinflammation,┬áthe production of self-targeted antibodies. Catena’s platform allows for the rapid coupling of proteins for the creation of novel therapeutics for cancer, vaccines, and autoimmune disorders. Our mission is to advance our best-in-class protein coupling technology to create novel biotherapeutic cures for autoimmune disorders through selective tolerance induction.